Roughly 40% of metastatic pancreatic ductal adenocarcinoma cases carry the RAS G12D mutation, and until recently that subtype lacked any targeted approach with Phase 3 momentum behind it. Revolution Medicines changed the calculus on Monday, announcing that patients are now being dosed in RASolute 305, a global, randomized, double-blind, placebo-controlled Phase 3 trial testing zoldonrasib added to investigator’s choice of modified FOLFIRINOX or gemcitabine plus nab-paclitaxel in previously untreated metastatic RAS G12D PDAC. The trial carries dual primary endpoints: progression-free survival and overall survival.
The strategic logic here is layered. Revolution’s RAS(ON) inhibitor program scored a meaningful proof-of-concept earlier this year when daraxonrasib, the company’s multi-selective RAS(ON) inhibitor, produced a statistically significant overall survival benefit in the Phase 3 RASolute 302 trial for previously treated metastatic PDAC across a range of RAS genotypes. That second-line readout matters here because it establishes that direct RAS(ON) inhibition can move the survival needle in pancreatic cancer, not just suppress tumor markers. Zoldonrasib is a distinct molecule, a covalent, G12D-selective tri-complex inhibitor that recruits cyclophilin A to lock onto the active oncogenic form of the protein. The question RASolute 305 is asking is whether the G12D-selective approach, layered onto frontline chemotherapy, can do better than chemotherapy alone in the patients who carry that specific mutation and who historically face worse outcomes than some other RAS-mutant subgroups.
The trial design reflects deliberate caution about patient selection. By restricting enrollment to G12D-confirmed cases and running a blinded placebo backbone, the study avoids the confounding that has plagued earlier pancreatic cancer combination trials where biomarker heterogeneity obscured signal. Approved RAS-targeted therapies to date have focused on the G12C variant, leaving the G12D population without a matched targeted option. RASolute 305 runs in parallel with RASolute 303, which tests daraxonrasib in the first-line setting across broader RAS genotypes, giving Revolution two simultaneous Phase 3 bets at the front of the treatment course in the same disease.
The single number worth watching as this trial matures is the progression-free survival hazard ratio at the first pre-specified interim analysis. A strong PFS separation would justify the dual-primary design and signal early whether the combination clears the threshold that a second primary OS readout would need to confirm. That interim will define whether RASolute 305 stays on its current trajectory or forces a protocol reassessment before the overall survival data have time to mature.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
